- Conditions
- Blepharitis
- Interventions
- KPI-121, Vehicle
- Drug
- Lead sponsor
- Kala Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Artesia, California • Mission Hills, California + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Ocular Infections, Irritations and Inflammations
- Interventions
- KPI-121 0.25%, KPI-121 1.0%, Vehicle of KPI-121 0.25%, Vehicle of KPI-121 1.0%
- Drug
- Lead sponsor
- Kala Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 23
- States / cities
- Artesia, California • Mission Hills, California • Rancho Cordova, California + 17 more
- Conditions
- Kerato Conjunctivitis Sicca
- Interventions
- KPI-121 Ophthalmic Suspension, Vehicle
- Drug
- Lead sponsor
- Kala Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 901 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 64 more
- Conditions
- Dry Eye Syndromes, Keratoconjunctivitis Sicca
- Interventions
- KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
- Drug
- Lead sponsor
- Kala Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 918 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 60
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 53 more
- Conditions
- Dry Eye Syndromes, Keratoconjunctivitis Sicca
- Interventions
- KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
- Drug
- Lead sponsor
- Kala Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 909 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Jonesboro, Arkansas + 54 more
- Conditions
- Dry Eye Syndromes, Keratoconjunctivitis Sicca
- Interventions
- KPI-121, Placebo
- Drug
- Lead sponsor
- Kala Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 11
- States / cities
- Artesia, California • Mission Hills, California • Rancho Cordova, California + 8 more
- Conditions
- Retinal Vein Occlusion, Diabetic Macular Edema
- Interventions
- KPI-121 0.25% Ophthalmic Suspension, KPI-121 1.0% Ophthalmic Suspension
- Drug
- Lead sponsor
- Kala Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 2
- States / cities
- Beverly Hills, California • Boston, Massachusetts